MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect

Researchers at MILabs B.V. have succeeded at imaging the popular Zirconium-89 (89Zr) isotope in small animals of human disease at very high resolutions (<0.75 mm). 89Zr as used for Positron Emission Tomography (PET) has great appeal to immune-oncology researchers because it is a nearly ideal radioisotope for PET imaging with immunoconjugates, as it possesses a multi-day physical half-life that is compatible with the in vivo pharmacokinetics of antibodies. Unfortunately, its positron-rage of 1.3-3.9mm and background of high energy prompt gamma’s causes non-isotropic blurring and haziness in the PET images of small laboratory animals making quantification and mapping of tumor heterogeneity in mouse oncology models virtually impossible. Quantification of tracer uptake and accurate assessment of tumor heterogeneity is considered by cancer researchers as essential for the development of effective therapies.

MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect

By using information of prompt photon emissions and advanced modeling of high energy photon transport during image reconstruction, the researchers at MILabshave succeeded at dramatically improving the three-dimensional imaging precision over conventional PET. Moreover, since MILabs’ PET systems can image multiple isotopes, 89Zr-immunoPET therapies and 18F-FDG cancer staging can now be performed simultaneously in the same animal at high-resolution to augment cancer therapy research.

Prof. Frederik Beekman, CEO/CSO MILabs states:

We are exited that we have been able to complete our mission of making imaging clear for difficult PET isotopes by eliminating the positron range blurring effect from small animal imaging for three important PET isotopes: 82Rb for cardiac imaging, 124I for e.g. oncolytic virus therapy imaging and now 89Zr for immunotherapy imaging.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MILabs. (2020, February 19). MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect. News-Medical. Retrieved on October 21, 2020 from https://www.news-medical.net/news/20200219/MILabs-achieves-breakthrough-in-preclinical-oncology-imaging-by-eliminating-positron-range-blurring-effect.aspx.

  • MLA

    MILabs. "MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect". News-Medical. 21 October 2020. <https://www.news-medical.net/news/20200219/MILabs-achieves-breakthrough-in-preclinical-oncology-imaging-by-eliminating-positron-range-blurring-effect.aspx>.

  • Chicago

    MILabs. "MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect". News-Medical. https://www.news-medical.net/news/20200219/MILabs-achieves-breakthrough-in-preclinical-oncology-imaging-by-eliminating-positron-range-blurring-effect.aspx. (accessed October 21, 2020).

  • Harvard

    MILabs. 2020. MILabs achieves breakthrough in preclinical oncology imaging by eliminating positron range blurring effect. News-Medical, viewed 21 October 2020, https://www.news-medical.net/news/20200219/MILabs-achieves-breakthrough-in-preclinical-oncology-imaging-by-eliminating-positron-range-blurring-effect.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
RWTH Aachen chooses MILabs’ hybrid OI/CT system to enhance molecular imaging research